Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03977467
Title Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

renal cell carcinoma

triple-receptor negative breast cancer

Therapies

Atezolizumab + Carboplatin

Atezolizumab + Tiragolumab

Atezolizumab + Cisplatin

Atezolizumab + Bevacizumab + Carboplatin

Atezolizumab + Bevacizumab + Cisplatin

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.